Inherited Metabolic Disorders
Applied Therapeutics Inc. is focused on Sorbitol Dehydrogenase (SORD) Deficiency, a rare inherited condition affecting carbohydrate metabolism and neuromuscular function. Its clinical research in this area centers on disease-specific therapeutic development for patients with unmet medical need.
- Sorbitol Dehydrogenase (SORD) Deficiency
- Inherited metabolic disease
- Rare disease therapy
The sponsor’s clinical activity reflects interest in conditions where metabolic dysfunction is linked to progressive functional impairment.
Neuromuscular Function
Research activity includes treatment of motor impairment associated with SORD-related disease, with attention to walking ability and broader physical performance in affected patients. The therapeutic scope includes outcomes relevant to daily mobility and muscle function.
- Walking performance
- Motor disability
- Muscle function
This area highlights clinical interest in preserving or improving functional capacity in a neuromuscular disorder.
Biomarker and Pharmacodynamic Assessment
The sponsor also investigates blood sorbitol as a disease-related biomarker, linking biochemical change with therapeutic response in SORD Deficiency. This reflects a focus on measurable metabolic signals relevant to target engagement and disease monitoring.
- Blood sorbitol
- Pharmacodynamic markers
- Disease biomarker monitoring
Such work is relevant to understanding how treatment affects the underlying metabolic pathway involved in the disorder.
Rare Disease Clinical Development
Applied Therapeutics Inc. is active in clinical research for a rare genetic disease population spanning adolescents and adults, with studies conducted across multiple sites and countries. The therapeutic interest lies in advancing targeted care for a narrowly defined patient group.
- Rare genetic disease
- Adolescent and adult patients
- Multinational clinical research
The portfolio shows concentration on a single specialized disease area within orphan disease research.
